Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($1.04), $0.11 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $360 thousand versus the consensus estimate of $137.5 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.